Sanofi Future Growth

Future criteria checks 3/6

Sanofi is forecast to grow earnings and revenue by 17.9% and 5.3% per annum respectively. EPS is expected to grow by 18.9% per annum. Return on equity is forecast to be 14.1% in 3 years.

Key information

17.9%

Earnings growth rate

18.9%

EPS growth rate

Pharmaceuticals earnings growth	19.6%
Revenue growth rate	5.3%
Future return on equity	14.1%
Analyst coverage	Good
Last updated	18 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0A2V - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	53,062	9,805	10,010	N/A	15
12/31/2025	49,934	9,462	9,054	N/A	16
12/31/2024	46,555	6,855	7,142	N/A	15
9/30/2024	48,445	4,506	N/A	N/A	N/A
6/30/2024	47,080	4,216	4,138	8,118	N/A
3/31/2024	46,288	4,538	N/A	N/A	N/A
12/31/2023	46,033	5,400	7,234	10,258	N/A
9/30/2023	45,699	9,066	N/A	N/A	N/A
6/30/2023	46,045	8,617	8,107	10,264	N/A
3/31/2023	46,199	8,357	N/A	N/A	N/A
12/31/2022	45,389	8,371	8,325	10,526	N/A
9/30/2022	44,348	6,409	N/A	N/A	N/A
6/30/2022	42,039	6,643	7,594	9,620	N/A
3/31/2022	40,342	6,666	N/A	N/A	N/A
12/31/2021	39,175	6,223	8,479	10,522	N/A
9/30/2021	38,496	6,174	N/A	N/A	N/A
6/30/2021	37,546	5,777	5,827	8,219	N/A
3/31/2021	36,939	12,197	N/A	N/A	N/A
12/31/2020	37,369	12,294	5,335	7,418	N/A
9/30/2020	37,650	11,224	N/A	N/A	N/A
6/30/2020	37,692	11,138	6,834	8,491	N/A
3/31/2020	38,234	3,453	N/A	N/A	N/A
12/31/2019	37,631	2,855	5,928	7,715	N/A
9/30/2019	36,940	3,179	N/A	N/A	N/A
6/30/2019	36,763	3,591	4,958	6,953	N/A
3/31/2019	36,264	4,439	N/A	N/A	N/A
12/31/2018	35,677	4,319	3,570	5,547	N/A
9/30/2018	35,316	4,041	N/A	N/A	N/A
6/30/2018	34,985	3,243	N/A	6,596	N/A
3/31/2018	35,428	3,539	N/A	N/A	N/A
12/31/2017	36,221	3,773	N/A	7,379	N/A
9/30/2017	36,400	4,593	N/A	N/A	N/A
6/30/2017	36,315	4,744	N/A	8,133	N/A
3/31/2017	35,677	4,682	N/A	N/A	N/A
12/31/2016	34,696	4,395	N/A	7,838	N/A
9/30/2016	34,349	4,195	N/A	N/A	N/A
6/30/2016	34,115	4,154	N/A	8,122	N/A
3/31/2016	34,569	4,440	N/A	N/A	N/A
12/31/2015	34,861	4,411	N/A	8,920	N/A
9/30/2015	37,201	5,292	N/A	N/A	N/A
6/30/2015	32,910	4,628	N/A	8,561	N/A
3/31/2015	35,074	4,329	N/A	N/A	N/A
12/31/2014	31,999	4,273	N/A	7,690	N/A
9/30/2014	33,484	4,112	N/A	N/A	N/A
6/30/2014	33,134	4,140	N/A	7,463	N/A
3/31/2014	33,074	3,812	N/A	N/A	N/A
12/31/2013	31,291	3,639	N/A	6,954	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0A2V's forecast earnings growth (17.9% per year) is above the savings rate (2.1%).

Earnings vs Market: 0A2V's earnings (17.9% per year) are forecast to grow faster than the UK market (14.6% per year).

High Growth Earnings: 0A2V's earnings are forecast to grow, but not significantly.

Revenue vs Market: 0A2V's revenue (5.3% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: 0A2V's revenue (5.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0A2V's Return on Equity is forecast to be low in 3 years time (14.1%).

Sanofi Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Sanofi Announces Board and Committee Appointments

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies